Cargando…
mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients
PURPOSE: This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine and explore the risk perception of COVID-19 in allogeneic hematopoietic stem cell transplant (HCT) recipients. METHODS: We performed a single-center prospective study in...
Autores principales: | Albiol, Nil, Aso, Olga, Gómez-Pérez, Lucía, Triquell, Mercè, Roch, Nerea, Lázaro, Elisabeth, Esquirol, Albert, González, Iria, López-Contreras, Joaquín, Sierra, Jorge, Martino, Rodrigo, García-Cadenas, Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517991/ https://www.ncbi.nlm.nih.gov/pubmed/36169731 http://dx.doi.org/10.1007/s00520-022-07376-w |
Ejemplares similares
-
Correction to: mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients
por: Albiol, Nil, et al.
Publicado: (2022) -
P1534: MRNA-1273 SARS-COV-2 VACCINE IN RECENTLY TRANSPLANTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: CELLULAR AND HUMORAL IMMUNE RESPONSES AND BOOSTER EFFECT
por: Albiol, Nil, et al.
Publicado: (2023) -
mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect
por: Albiol, Nil, et al.
Publicado: (2023) -
Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation
por: Martino, Rodrigo, et al.
Publicado: (2021) -
Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
por: Kum, Elena, et al.
Publicado: (2021)